MCID: HYP263
MIFTS: 41

Hypersomnia

Categories: Mental diseases, Neuronal diseases

Aliases & Classifications for Hypersomnia

MalaCards integrated aliases for Hypersomnia:

Name: Hypersomnia 53 17 71

Classifications:



External Ids:

UMLS 71 C0917799

Summaries for Hypersomnia

NINDS : 53 Hypersomnia is characterized by recurrent episodes of excessive daytime sleepiness or prolonged nighttime sleep. Different from feeling tired due to lack of or interrupted sleep at night, persons with hypersomnia are compelled to nap repeatedly during the day, often at inappropriate times such as at work, during a meal, or in conversation. These daytime naps usually provide no relief from symptoms. Patients often have difficulty waking from a long sleep, and may feel disoriented. Other symptoms may include anxiety, increased irritation, decreased energy, restlessness, slow thinking, slow speech, loss of appetite, hallucinations, and memory difficulty. Some patients lose the ability to function in family, social, occupational, or other settings. Hypersomnia may be caused by another sleep disorder (such as narcolepsy or sleep apnea), dysfunction of the autonomic nervous system, or drug or alcohol abuse. In some cases it results from a physical problem, such as a tumor, head trauma, or injury to the central nervous system. Certain medications, or medicine withdrawal, may also cause hypersomnia. Medical conditions including multiple sclerosis, depression, encephalitis, epilepsy, or obesity may contribute to the disorder. Some people appear to have a genetic predisposition to hypersomnia; in others, there is no known cause. Typically, hypersomnia is first recognized in adolescence or young adulthood.

MalaCards based summary : Hypersomnia is related to idiopathic hypersomnia and recurrent hypersomnia, and has symptoms including excessive daytime somnolence, snoring and sleep disturbances. An important gene associated with Hypersomnia is HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1), and among its related pathways/superpathways are Translocation of ZAP-70 to Immunological synapse and MHC class II antigen presentation. The drugs Citalopram and Bupropion have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and eye.

Wikipedia : 74 Hypersomnia is a neurological disorder of excessive time spent sleeping or excessive sleepiness. It can... more...

Related Diseases for Hypersomnia

Diseases in the Hypersomnia family:

Recurrent Hypersomnia

Diseases related to Hypersomnia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 243)
# Related Disease Score Top Affiliating Genes
1 idiopathic hypersomnia 34.4 HLA-DQB1 HCRT
2 recurrent hypersomnia 34.0 HLA-DQB1 HCRT
3 kleine-levin hibernation syndrome 32.9 HLA-DQB1 HCRT
4 neuromyelitis optica 30.2 HLA-DRB1 HCRT
5 whipple disease 29.7 HLA-DRB1 HLA-DQB1
6 acute disseminated encephalomyelitis 29.6 HLA-DRB1 HLA-DQB1 HCRT
7 narcolepsy 29.4 HLA-DRB1 HLA-DQB1 HCRT CPT1B CHKB
8 narcolepsy 2 29.2 HLA-DRB1 HLA-DQB1 HCRT
9 guillain-barre syndrome 29.2 HLA-DRB1 HLA-DQB1 HCRT
10 obsolete: idiopathic hypersomnia without long sleep time 12.2
11 obsolete: idiopathic hypersomnia with long sleep time 12.2
12 sleep disorder 11.6
13 major depressive disorder 11.6
14 dystonia, dopa-responsive, due to sepiapterin reductase deficiency 11.5
15 myotonic dystrophy 2 11.2
16 atypical depressive disorder 11.2
17 sleep apnea 10.7
18 depression 10.4
19 major affective disorder 8 10.4
20 major affective disorder 9 10.4
21 bipolar disorder 10.4
22 mood disorder 10.4
23 mental depression 10.4
24 myotonic dystrophy 10.3
25 encephalitis 10.3
26 encephalopathy 10.3
27 prader-willi syndrome 10.2
28 traumatic brain injury 10.2
29 restless legs syndrome 10.2
30 dysthymic disorder 10.2
31 brain injury 10.2
32 apnea, obstructive sleep 10.1
33 multiple sclerosis 10.1
34 movement disease 10.1
35 migraine with or without aura 1 10.1
36 ocular motor apraxia 10.1
37 stroke, ischemic 10.1
38 delayed sleep phase disorder 10.1
39 cerebrovascular disease 10.1
40 rem sleep behavior disorder 10.1
41 neuromyelitis optica spectrum disorder 10.1
42 limbic encephalitis with lgi1 antibodies 10.0 HLA-DRB1 HLA-DQB1
43 autoimmune polyglandular syndrome type 3 10.0 HLA-DRB1 HLA-DQB1
44 primary adrenal insufficiency 10.0 HLA-DRB1 HLA-DQB1
45 type ii mixed cryoglobulinemia 10.0 HLA-DRB1 HLA-DQB1
46 moyamoya angiopathy 10.0 HLA-DRB1 HLA-DQB1
47 recurrent respiratory papillomatosis 10.0 HLA-DRB1 HLA-DQB1
48 beryllium disease 10.0 HLA-DRB1 HLA-DQB1
49 apple allergy 10.0 HLA-DRB1 HLA-DQB1
50 chronic beryllium disease 10.0 HLA-DRB1 HLA-DQB1

Graphical network of the top 20 diseases related to Hypersomnia:



Diseases related to Hypersomnia

Symptoms & Phenotypes for Hypersomnia

UMLS symptoms related to Hypersomnia:


excessive daytime somnolence, snoring, sleep disturbances, sleeplessness, insomnia with sleep apnea, unspecified, hypersomnia with sleep apnea, unspecified, disruption of 24 hour sleep wake cycle, unspecified, [d]sleep disturbances (& [hypersomnia] or [insomnia])

Drugs & Therapeutics for Hypersomnia

Drugs for Hypersomnia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 80)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Citalopram Approved Phase 4 59729-33-8 2771
2
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
3
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
4 Psychotropic Drugs Phase 4
5 Antiparkinson Agents Phase 4
6 Muscarinic Antagonists Phase 4
7 Antidepressive Agents Phase 4
8 Cholinergic Agents Phase 4
9 Cholinergic Antagonists Phase 4
10 Parasympatholytics Phase 4
11 Tranquilizing Agents Phase 4
12 Antipsychotic Agents Phase 4
13 Quetiapine Fumarate Phase 4 111974-72-2
14
Sodium oxybate Approved Phase 2, Phase 3 502-85-2 5360545
15
Sodium citrate Approved, Investigational Phase 2, Phase 3 68-04-2
16
Lithium carbonate Approved Phase 3 554-13-2
17
Paroxetine Approved, Investigational Phase 3 61869-08-7 43815
18
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 2, Phase 3 53-43-0 9860744
19
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
20
Citric acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 77-92-9 311
21 Adjuvants, Immunologic Phase 2, Phase 3
22 DHEA (Dehydroepiandrosterone) Phase 2, Phase 3
23 Immunologic Factors Phase 2, Phase 3
24 Pharmaceutical Solutions Phase 3
25 Adjuvants, Anesthesia Phase 2, Phase 3
26 Citrate Phase 2, Phase 3
27 Cytochrome P-450 Enzyme Inhibitors Phase 3
28 Serotonin Uptake Inhibitors Phase 3
29 Serotonin Agents Phase 3
30 Cytochrome P-450 CYP2D6 Inhibitors Phase 3
31 Antimanic Agents Phase 3
32
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
33
Flumazenil Approved Phase 1, Phase 2 78755-81-4 3373
34
Cocaine Approved, Illicit Phase 2 50-36-2 5760 446220
35
Nicotine Approved Phase 2 54-11-5 942 89594
36
Clarithromycin Approved Phase 2 81103-11-9 84029
37
Dopamine Approved Phase 2 51-61-6, 62-31-7 681
38
Amphetamine Approved, Illicit, Investigational Phase 2 300-62-9 5826 3007
39
Dextroamphetamine Approved, Illicit Phase 2 51-64-9 5826
40 Central Nervous System Stimulants Phase 2
41 GABA Modulators Phase 1, Phase 2
42 Protective Agents Phase 1, Phase 2
43 Antidotes Phase 1, Phase 2
44 Anesthetics, Local Phase 2
45 Vasoconstrictor Agents Phase 2
46 Nicotinic Agonists Phase 2
47 GABA Agents Phase 2
48 Convulsants Phase 2
49 Pentylenetetrazole Phase 2 54-95-5
50 Cytochrome P-450 CYP3A Inhibitors Phase 2

Interventional clinical trials:

(show top 50) (show all 54)
# Name Status NCT ID Phase Drugs
1 Pilot Study: The Effect of Rozerem on Sleep Disturbance After Traumatic Brain Injury Unknown status NCT01207050 Phase 4 Ramelteon
2 Neuroimaging Study of Bupropion Treatment in Patients With Major Depressive Disorder Completed NCT01541475 Phase 4 Bupropion, Escitalopram;Escitalopram
3 Melancholic Depression and Insomnia as Predictors of Response to Quetiapine in Patients With Major Depression Completed NCT03207438 Phase 4 Quetiapine 50 MG Extended Release Oral Tablet;Quetiapine Fumarate XR 150-300 mg;Placebos
4 A Randomized, Double-Blind Study of Placebo vs. Ketamine For Use During Dressing Changes in Critically Ill Burn Patients Withdrawn NCT02336308 Phase 4 Ketamine;Placebo, Normal Saline
5 Phase 3 Study of Oral Dehydroepiandrosterone (DHEA) in Adults With Myotonic Dystrophy Completed NCT00167609 Phase 2, Phase 3 dehydroepiandrosterone 100 and 400 mg
6 St. John's Wort Extract LI 160 for the Treatment of Atypical Depression Completed NCT00861978 Phase 3 St. John's Wort extract;Placebo
7 A Double-blind, Placebo-controlled, Randomized Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension Recruiting NCT03533114 Phase 3 JZP-258;Placebo Oral Solution
8 A Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Tolerance of Sodium Oxybate in Patients Affected With Idiopathic Hypersomnia Recruiting NCT03597555 Phase 2, Phase 3 Sodium Oxybate Oral Solution 500 MG/ML;Placebos
9 The Role of Palliative Care Interventions to Reduce Circadian Rhythm Disorders in Persons With Dementia: The Healthy Patterns Study Recruiting NCT03682185 Phase 3
10 A Randomized, Double-blind, Double-dummy, Controlled Trial of Lithium Versus Paroxetine in Subjects With Major Depression Who Have a Family History of Bipolar Disorder or Completed Suicide - a Pilot Study Terminated NCT00400088 Phase 3 paroxetine;lithium
11 A Randomized, Placebo-Controlled, Double-blind, Fixed-Dose, Multiple Cohort, Multiple Crossover, Dose-Finding Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2 Completed NCT02512588 Phase 2 BTD-001;Placebo
12 Clarithromycin for the Treatment of Hypersomnia Completed NCT01146600 Phase 2 Clarithromycin followed by placebo;Placebo then Clarithromycin
13 A Ten Subject, Double-Blind, Placebo-Controlled Trial of Single Day Dosing of Sublingual Flumazenil in Individuals With Primary Hypersomnia or Excessively Long Total Sleep Time and Excess Endogenous Potentiation of GABA-A Receptors Completed NCT01183312 Phase 1, Phase 2 Flumazenil
14 Combined Treatment of Modafinil and Cognitive Behavioral Therapy for Cocaine Dependence Completed NCT00344565 Phase 2 Modafinil
15 Uncontrolled Pilot Trial of Transnasal Nicotine in Parkinson Disease Completed NCT03865121 Phase 2 Nicotine Nasal Spray 10 MG/ML (0.5 MG/SPRAY)
16 A Randomized, Placebo-Controlled, Double-Blind, Crossover Study of Oral BTD-001 in Adults With Idiopathic Hypersomnia Recruiting NCT03542851 Phase 2 Pentetrazol (PTZ);Placebo oral capsule
17 Antibiotic-mediated Improvements in Vigilance: Mechanisms of Action of Clarithromycin in Hypersomnia Syndromes Recruiting NCT04026958 Phase 2 Clarithromycin;Placebo
18 Informing Treatment Decisions in the Central Disorders of Hypersomnolence: A Pragmatic Clinical Trial of Modafinil Versus Amphetamines Recruiting NCT03772314 Phase 2 Modafinil;Amphetamine-Dextroamphetamine
19 Double-Blind, Placebo-Controlled, Dose-Range-Finding, Crossover Trial of Single Day Administration of ERX-963 in Adults With Myotonic Dystrophy Type 1 Recruiting NCT03959189 Phase 1 ERX-963;Placebo
20 A Phase 1b Randomized, Double-Blind, Placebo-Controlled, Crossover Study of a Single Intravenous Infusion Dose of TAK-925 in Patients With Idiopathic Hypersomnia Not yet recruiting NCT04091438 Phase 1 TAK-925;TAK-925 Placebo
21 Importance of Sleep Deprivation in Differential Diagnosis of Primary Hypersomnia in Reference Centers Rare Hypersomnia Unknown status NCT03459300
22 PET-MRI F-DOPA Activity in the Mesocorticolimbic System and Depressive Symptoms in the Prediction of Treatment Compatibility Unknown status NCT03026309
23 Cardiovascular Variability and Heart Rate Arousal Response in Idiopathic Hypersomnia Completed NCT02913651
24 Evaluation of Excessive Diurnal Sleepiness by the Expression and Activity of Salivary Amylase in Children With Hypersomnia. Completed NCT01926405
25 Psychosocial Adjunctive Treatment for Hypersomnia (PATH): A Pilot Trial Completed NCT03904238
26 Follow-up of the Therapeutic Coverage by Continuous Positive Pressure of the Obstructive Sleep Apnea Syndrome for Down Syndrome Patients Completed NCT00394290
27 Improving the Assessment of Hypersomnolence Completed NCT02884505
28 Training Protocol for Various Sleep Disorders in Patients With Neurological Disorders Completed NCT00001664
29 Neurophysiologic Correlates of Hypersomnia: a High Density EEG Investigation Completed NCT01719315
30 Development and Evaluation of a Sleep-coaching Program Completed NCT02896062
31 Brief Sleep Intervention for Suicide in Bipolar Disorder Completed NCT01764074
32 Prevalence of Sleep Disturbances in Psoriasis Completed NCT00895375
33 A Transdiagnostic Sleep and Circadian Treatment to Improve Community SMI Outcomes Completed NCT02469233
34 The Effects of Mindfulness on Disrupted Sleep in Bipolar Disorder Completed NCT01764035
35 Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies, Impact of Modafinil Treatment. Completed NCT00916253 Modafinil;Placebo
36 Effect of CPAP Treatment in the Control of Refractory Hypertension Completed NCT00616265
37 Population-bases Study to Asses Prevalence of Sleep Disorders and Their Association With Cardiovascular Risk Factors and Diseases Completed NCT01877616
38 A Pilot Study to Evaluate Individualized Choice of Antidepressant in Patients With Cancer Completed NCT01725048 Early Phase 1 Mirtazapine;Citalopram
39 Diagnosis, Cost and Therapeutic Decision-Making of Home Respiratory Polygraphy for Patients Without High Suspicion of OSA or With Comorbidity - Hospital Polysomnography in Comparison With Three Nights of Home Respiratory Polygraphy Completed NCT01820156
40 Feasibility Study Regarding the Implantation and Use of Rechargeable Neurostimulators in Deep Brain Stimulation for Psychiatric Disorders (Either Obsessive-compulsive Disorder or Major Depression) Completed NCT02685280
41 Investigating Cognitive/Affective/Sleep Symptoms During High-dose Interleukin-2 Therapy Completed NCT02150369
42 Hypersomnia in Major Depressive Disorder Recruiting NCT04006834
43 Open-label Clinical Trial to Evaluate the Efficacy of Sodium Oxybate (Xyrem®) in the Treatment of Two Under-recognized Clinical Conditions: Post-traumatic Narcolepsy and Post-traumatic Hypersomnia Recruiting NCT03626727 Early Phase 1 Sodium Oxybate Oral Solution [Xyrem]
44 Constitution of a Clinical, Neurophysiological and Biological Cohort for Chronic Sleep Disorders Responsible of Hypersomnolence Recruiting NCT03998020
45 Transcranial Direct Current Stimulation Therapy for Central Hypersomnia Without Cataplexy Recruiting NCT03198156
46 Validation of Non-invasive Miniature Optical Sensors for Scoring Sleep Stages: a Prospective, Method-comparison, Proof of Concept, Single-centre Phase IV Study Recruiting NCT03823105
47 The Role of the Circadian System in Neurological Sleep-wake Disorders: Assessment of Circadian and Homeostatic Sleep-wake Regulation and Vigilance With a Poly-nap Protocol Recruiting NCT03356938
48 Microglial Activation in Narcolepsy Type 1: Positron Emission Tomography (PET) Study in [18F] DPA-714 Recruiting NCT03754348
49 Coordination of Rare Diseases at Sanford Recruiting NCT01793168
50 Impact of Maxillomandibular Advancement Upon the Pharyngeal Airway Volume and the Apnea-hypopnea Index in the Treatment of Obstructive Sleep Apnea Enrolling by invitation NCT03796078

Search NIH Clinical Center for Hypersomnia

Genetic Tests for Hypersomnia

Anatomical Context for Hypersomnia

MalaCards organs/tissues related to Hypersomnia:

40
Brain, Testes, Eye, Hypothalamus, Heart, Pituitary, T Cells

Publications for Hypersomnia

Articles related to Hypersomnia:

(show top 50) (show all 1778)
# Title Authors PMID Year
1
Improvement in hypersomnia with high frequency repetitive transcranial magnetic stimulation in depressed adolescents: Preliminary evidence from an open-label study. 61
31634515 2020
2
Sleep disturbances among older adults following traumatic brain injury. 61
31547739 2020
3
Obstructive Sleep Apnea and Arterial Hypertension: Implications of Treatment Adherence. 61
32016549 2020
4
Frequency and Severity of Autonomic Symptoms in Idiopathic Hypersomnia. 61
32039754 2020
5
Association of Inattention, Hyperactivity, and Hypersomnolence in Two Clinic-Based Adult Cohorts. 61
29771183 2020
6
Event marker compliance in actigraphy. 61
31617625 2020
7
Grief-induced reversible cerebral vasoconstriction syndrome (RCVS). 61
31996381 2020
8
Symptomatic Narcolepsy/Cataplexy in a Dog with Brainstem Meningoencephalitis of Unknown Origin. 61
31961221 2020
9
A Clinical Diagnostic System for Late-Stage Neuropsychiatric Lyme Borreliosis Based upon an Analysis of 100 Patients. 61
31935905 2020
10
"Do depressive and manic symptoms differentially impact on functioning in acute depression? Results from a large, cross-sectional study". 61
31600585 2020
11
Neuromyelitis optica spectrum disorder with severe orthostatic hypotension due to hypothalamic lesions. 61
32036263 2020
12
Seasonal variation in specific depressive symptoms: A population based study. 61
31630036 2020
13
Focusing on insomnia symptoms to better understand depression: A STAR*D report. 61
31499373 2020
14
Symptomatology differences of major depression in psychiatric versus general hospitals: A machine learning approach. 61
31521873 2020
15
Eating, sleeping and sexual function disorders in women with polycystic ovary syndrome (PCOS): A systematic review and meta-analysis. 61
31917860 2020
16
Simple behavioral criteria for the diagnosis of disorders of arousal. 61
31957639 2020
17
Targeted recombination in active populations as a new mouse genetic model to study sleep-active neuronal populations: Demonstration that Lhx6+ neurons in the ventral zona incerta are activated during paradoxical sleep hypersomnia. 61
31943457 2020
18
The need for functional magnetic resonance spectroscopy studies in idiopathic hypersomnia. 61
31930345 2020
19
Topical Review: A Biopsychosocial Framework for Pediatric Narcolepsy and Idiopathic Hypersomnia. 61
31670813 2020
20
Simple behavioral criteria for the diagnosis of disorders of arousal. 61
31797765 2019
21
Relationship of rare disorder latent clusters to anxiety and depression symptoms. 61
31855040 2019
22
The Epidemiology of Patient-Reported Hypersomnia in Persons With Advanced Age. 61
31390046 2019
23
Effects of Pharmacotherapy Treatment on Patient-Reported Outcomes in a Narcolepsy and Idiopathic Hypersomnia Cohort. 61
31855165 2019
24
A missense variant in PER2 is associated with delayed sleep-wake phase disorder in a Japanese population. 61
31527662 2019
25
TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice. 61
31654653 2019
26
[A case of suspected neuromyelitis optica spectrum disorder preceded by aseptic meningitis-like symptoms]. 61
31656264 2019
27
Serotonergic system may be involved in alterations of sleep homeostasis in spontaneously hypertensive rats. 61
31726489 2019
28
Secondary hypersomnia as an initial manifestation of neuromyelitis optica spectrum disorders. 61
31785490 2019
29
Subjective and objective features of sleep disorders in patients with acute ischemic or haemorrhagic stroke: It is not only sleep apnoea which is important. 61
31837521 2019
30
Comparison of Genetic Liability for Sleep Traits Among Individuals With Bipolar Disorder I or II and Control Participants. 61
31751445 2019
31
Usefulness of brain SPECT imaging in the study of recurrent hypersomnia: Kleine-Levin syndrome. 61
28869046 2019
32
Obstructive sleep apnoea with co existent Kleine-Levine syndrome in a middle-aged man. 61
31850697 2019
33
Development and validation of the Hypersomnia Severity Index (HSI): A measure to assess hypersomnia severity and impairment in psychiatric disorders. 61
31494450 2019
34
Prevalence of seasonal depression in a prospective cohort study. 61
30022319 2019
35
Does early and late life depression differ in residual symptoms, functioning and quality of life among the first-episode major depressive patients. 61
31731143 2019
36
Do sleep disturbances contribute to cognitive impairments in schizophrenia spectrum and bipolar disorders? 61
31587109 2019
37
Systematic review and meta-analysis of the relationship between sleep disorders and suicidal behaviour in patients with depression. 61
31623600 2019
38
Using network analysis to examine links between individual depressive symptoms, inflammatory markers, and covariates. 61
31615595 2019
39
Association of Use of Oral Contraceptives With Depressive Symptoms Among Adolescents and Young Women. 61
31577333 2019
40
Beyond sleepy: structural and functional changes of the default-mode network in idiopathic hypersomnia. 61
31328786 2019
41
Depressive symptoms mediate the relationship between sleep disturbances and type 2 diabetes mellitus. 61
31626387 2019
42
Effects of Pharmacotherapy Treatment on Patient-Reported Outcomes in a Narcolepsy and Idiopathic Hypersomnia Cohort. 61
31662179 2019
43
Growth Hormone Deficiency and Excessive Sleepiness: A Case Report and Review of the Literature. 61
31599135 2019
44
Vitamin B12 Deficiency: A Rare Cause of Excessive Daytime Sleepiness. 61
31538608 2019
45
Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors. 61
31488216 2019
46
Risk of obstructive sleep apnea among senegalese dialysis patients. 61
31696848 2019
47
Precision Medicine for Idiopathic Hypersomnia. 61
31375202 2019
48
Bilateral oculomotor nerve palsy in a case of anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. 61
31178306 2019
49
[Sleep quality and sexual functioning in healthy adults]. 61
31445903 2019
50
The role of CPAP treatment in elderly patients with moderate obstructive sleep apnoea: a multicentre randomised controlled trial. 61
31164429 2019

Variations for Hypersomnia

Expression for Hypersomnia

Search GEO for disease gene expression data for Hypersomnia.

Pathways for Hypersomnia

GO Terms for Hypersomnia

Cellular components related to Hypersomnia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 trans-Golgi network membrane GO:0032588 9.4 HLA-DRB1 HLA-DQB1
2 endocytic vesicle membrane GO:0030666 9.37 HLA-DRB1 HLA-DQB1
3 ER to Golgi transport vesicle membrane GO:0012507 9.32 HLA-DRB1 HLA-DQB1
4 transport vesicle membrane GO:0030658 9.26 HLA-DRB1 HLA-DQB1
5 clathrin-coated endocytic vesicle membrane GO:0030669 9.16 HLA-DRB1 HLA-DQB1
6 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 8.96 HLA-DRB1 HLA-DQB1
7 MHC class II protein complex GO:0042613 8.62 HLA-DRB1 HLA-DQB1

Biological processes related to Hypersomnia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 antigen processing and presentation of exogenous peptide antigen via MHC class II GO:0019886 9.37 HLA-DRB1 HLA-DQB1
2 interferon-gamma-mediated signaling pathway GO:0060333 9.32 HLA-DRB1 HLA-DQB1
3 antigen processing and presentation GO:0019882 9.26 HLA-DRB1 HLA-DQB1
4 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.16 HLA-DRB1 HLA-DQB1
5 humoral immune response mediated by circulating immunoglobulin GO:0002455 8.96 HLA-DRB1 HLA-DQB1
6 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 8.62 HLA-DRB1 HLA-DQB1

Molecular functions related to Hypersomnia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 8.96 HLA-DRB1 HLA-DQB1
2 MHC class II receptor activity GO:0032395 8.62 HLA-DRB1 HLA-DQB1

Sources for Hypersomnia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....